Rib-X initiates antibiotic drug trial
The trial is designed to evaluate multiple objective efficacy measures in order to support the design of the Phase 3 clinical studies. The randomised, double blind, Phase 2b
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
The NON outlined Health Canada’s concerns, which are focused mainly on chemistry, manufacturing, and control (CMC) and preclinical toxicology issues. Health Canada has requested additional information on polyglucose
The latest ENLIGHTEN release contains numerous enhancements such as expanded reporting capabilities that provide users with superior report creation flexibility and increased data visibility. The enhancements also include
The overall program from initiation to delivery of optimized liposome formulations of GAP-107B8 to PharmaGap suitable for in-vivo studies is expected to take approximately 4 months. Initial analysis